Denali Therapeutics (DNLI) EBITDA Margin (2018 - 2023)
Denali Therapeutics (DNLI) reported EBITDA Margin of 7779.24% for Q3 2023, up 4813271.0% year-over-year from N/an in Q3 2022, and down 12504.13% on a QoQ basis from 62.71% in Q2 2023.
Denali Therapeutics (DNLI) has 6 years of EBITDA Margin data on file, last reported at 7779.24% in Q3 2023.
- Quarterly EBITDA Margin rose 4813271.0% year-over-year to 7779.24% in Q3 2023, while the trailing twelve-month figure through Jun 2024 was 33218.0% (down 3318337.0% YoY) and the FY2023 annual result came in at 41.66%, up 968106.0% from the prior year.
- EBITDA Margin slipped to 7779.24% in Q3 2023 per DNLI's latest filing, from 62.71% in the prior quarter.
- Across five years, EBITDA Margin topped out at 77.22% in Q4 2020 and bottomed at 7002800.0% in Q1 2021.
- The 5-year median for EBITDA Margin is 1009.78% (2020), against an average of 445480.6%.
- The widest annual swing landed in 2021, when EBITDA Margin sank 689457308 bps; it then soared 700262921 bps in 2022.
- Tracing DNLI's EBITDA Margin over 5 years: stood at 1236.26% in 2019, then jumped by 106 bps to 77.22% in 2020, then slumped by 899 bps to 617.22% in 2021, then tumbled by 52 bps to 937.11% in 2022, then sank by 730 bps to 7779.24% in 2023.
- Per Business Quant, the three latest DNLI EBITDA Margin figures stand at 7779.24% (Q3 2023), 62.71% (Q2 2023), and 299.97% (Q1 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -7,779.24% |
| Jun 30, 2023 | 62.71% |
| Mar 31, 2023 | -299.97% |
| Dec 31, 2022 | -937.11% |
| Sep 30, 2022 | -55,911.96% |
| Jun 30, 2022 | -117.79% |
| Mar 31, 2022 | -170.79% |
| Dec 31, 2021 | -617.22% |
| Sep 30, 2021 | -1,603.42% |
| Jun 30, 2021 | -405.51% |
| Mar 31, 2021 | -7,002,800.00% |
| Dec 31, 2020 | 77.22% |
| Sep 30, 2020 | -1,175,360.00% |
| Jun 30, 2020 | -1,009.78% |
| Mar 31, 2020 | -108,226.92% |
| Dec 31, 2019 | -1,236.26% |
| Sep 30, 2019 | -48,517.71% |
| Jun 30, 2019 | -58,373.74% |
| Mar 31, 2019 | -903.95% |
| Dec 31, 2018 | 62.33% |
| Sep 30, 2018 | -2,953.47% |
| Jun 30, 2018 | -3,333.13% |
| Mar 31, 2018 | -3,837.29% |